Naslov
A randomized phase II study on the effects of 5-Aza-2"-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia : an EORTC Leukemia Cooperative Group phase II study (06893)

Autori
Willemze, R. ; Suciu, S. ; Archimbaud, E. ; Muus, P. ; Stryckmans, P. ; Louwagie, E.A. ; Berneman, Z. ; Tjean, M. ; Wijermans, P. ; Dohner, H. ; Jehn, U. ; Labar, Boris ; Jakšić, Branimir ; Dardenne, M. ; Zittoun, R.

Izvornik
Leukemia (0887-6924) 11 (1997), Suppl. 1; S 24-S 27

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
azacytidine; randomized trial; relapsed leukemia

Sažetak
5-Aza-2"-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia. Sixty-three patients received 5-Aza-2"-deoxycytidine 125 mg/m2 as a 6 h infusion every 12 h for 6 days in combination with either amsacrine 120 mg/m2 as a 1 h infusion on days 6 and 7 (n=30) or idarubicin 12 mg/m2 as a 15 min infusion on days 5, 6 and 7 (n = 33). Twenty-three patients (36.5%) obtained a complete remission (CR) ; eight of 30 patients treated with amsacrine and 15 of 33 treated with idarubicin. Patients with an interval of more than 1 year between initial diagnosis and start of the protocol achieved CR in 51.4%, compared to 15.4% for patients with an interval of less than 1 year. Patients with normal cytogenetics had a higher CR rate (61%) than those with abnormal cytogenetic findings (15.8%). Digestive tract and hematologic toxicity was prolonged, compared to standard induction schedules. Median disease-free survival was approximately 8 months, with only 20% of patients staying in remission for more than 1 year. 5-Aza-2"-deoxycytidine is a good antileukemic agent with considerable toxicity. Current results merit further investigations in previously untreated leukemia.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA